NEWPORT BEACH, Calif., July 25, 2017 /PRNewswire/ -- IACTA Pharmaceuticals, Inc. today announced that the technology used in its dry eye candidate
IACTA Pharmaceuticals partnered with UK-based Nanomerics, Ltd., a global leader in pharmaceutical research and the developer of MET. IACTA has an exclusive license for NM133, cyclosporine with MET, in North America.
"This award recognizes the significant role MET nanotechnology can play in novel methods of drug delivery. At IACTA we believe MET nanotechnology has enormous potential for superior delivery of cyclosporine to the tissues of the eye," said IACTA Pharmaceuticals Founder and CEO Damon Burrows. "We've found a great partner in Nanomerics, as this technology will empower IACTA to reach new heights in the innovative eyecare space."
Patients who suffer with moderate to severe Chronic Dry Eye often require prescription assistance to increase tear production. However, cyclosporine, an anti-inflammatory drug used to treat Chronic Dry Eye, is hydrophobic, which creates a challenge delivering the medicine to the eye given the water-based environment surrounding the eye. NM133 is a nano-enabled form of cyclosporine A, using MET to enable the potential for better transport of cyclosporine A to reach the tissues of the eye.
"We believe that NM133 has the potential to change the way we treat Chronic Dry Eye," said IACTA Pharmaceuticals Chief Development Officer Michael Adam. "The selection of MET for first prize from among dozens of applicants from across the globe reinforces our belief in the potential of MET and in NM133's potential as a superior candidate for delivery of cyclosporine A for the treatment of Chronic Dry Eye."
"The Nanomerics team was delighted to receive this award from the Royal Society of Chemistry. The recognition of the scientific and commercial development of MET platform by our peers has been very exciting," commented Nanomerics' CEO Andreas Schätzlein.
ABOUT IACTA PHARMACEUTICALS, INC.IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. The California-based company is dedicated to treating diseases, advancing technology, and improving patient outcomes. IACTA's lead investigational product, NM133, is being developed for the treatment of Chronic Dry Eye. For more information on IACTA Pharmaceuticals, Inc., visit: http://iactapharma.com/index.html.
ABOUT NANOMERICS, LTD.Founded in 2010, London-based Nanomerics is a leader in pharmaceutical nanotechnology. The company's nanomedicines know-how and proprietary technology platforms provide drug delivery solutions for poorly water-soluble drugs, nucleic acids, and peptides. For more information on Nanomerics and the company's proprietary Molecular Envelope Technology (MET), visit: http://www.nanomerics.com/.
@ 2017 IACTA Pharmaceuticals, Inc. All Rights Reserved.
View original content:http://www.prnewswire.com/news-releases/iacta-pharmaceuticals-licensed-technology-receives-royal-society-of-chemistry-award-300493645.html
SOURCE IACTA Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All